StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Gyre Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Gyre Therapeutics's EV/EBITDA was 231.5× on Jul 31, 2026, against 51.9× a year earlier. Over the last 4 years it ranged from 1.7× to 271.5×, with a median of 48.0×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Jul 31, 2026231.5×+108.7
2025Dec 31, 2025122.8×−7.6
2024Jan 31, 2024130.4×−141.1
2023Dec 29, 2023271.5×+252.1
2022Dec 30, 202219.4×−54.5
2013Jan 31, 201374.0×+10.2
2012Dec 31, 201263.8×+62.1
2011Dec 30, 20111.7×–

More Gyre Therapeutics figures

See a number that looks wrong?